Providence Health & Services Oregon
Providence Health & Services Oregon was paid $20.46M by Medicaid between Jan 2018 and Nov 2024, across 58 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
MILWAUKIE, OR 97222
Next to other Emergency Medicine Physician providers in Oregon
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,592 | $4.41M | |
| 2019 | 33,688 | $2.88M | |
| 2020 | 26,092 | $2.27M | |
| 2021 | 27,427 | $2.30M | |
| 2022 | 28,325 | $2.62M | |
| 2023 | 28,726 | $3.03M | |
| 2024incomplete | 25,442 | $2.94M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 27,956 | 23,470 | $7.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 36,175 | 29,972 | $5.79M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 17,274 | 14,870 | $5.40M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.3% | 10,856 | 9,501 | $1.09M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 3,897 | 3,722 | $286K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,542 | 5,525 | $184K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,664 | 4,059 | $150K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,280 | 778 | $122K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,822 | 1,597 | $54K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 329 | 303 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 536 | 495 | $22K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 232 | 215 | $10K |
46 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 39 | $8K |
| 80053 | Comprehensive metabolic panel | <1% | 31,850 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,710 | $6K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 819 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,388 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 91 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 126 | $1K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $919.27 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 152 | $740.42 |
| 80061 | Lipid panel | <1% | 95 | $714.89 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 116 | $574.27 |
| 83690 | <1% | 2,890 | $355.18 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 149 | $342.00 |
| 84484 | <1% | 2,608 | $272.42 | |
| 81025 | <1% | 860 | $266.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 611 | $249.96 |
| 81001 | <1% | 1,958 | $116.00 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,520 | $98.90 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12 | $93.48 |
| 84703 | <1% | 261 | $45.50 | |
| 85610 | <1% | 377 | $30.44 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 194 | $29.50 |
| 85730 | <1% | 280 | $23.42 | |
| 81003 | <1% | 441 | $18.00 | |
| 83605 | <1% | 66 | $8.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,800 | $6.65 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,765 | $5.14 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 4,048 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 502 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,108 | $0.00 |
| 84145 | 0% | 59 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 144 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 71 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 50 | $0.00 |
| 80305 | 0% | 12 | $0.00 | |
| 87631 | 0% | 16 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 32 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 246 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 627 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,468 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 27 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 27 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 30 | $0.00 |
| 83880 | 0% | 16 | $0.00 | |
| 92567 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.